CORMORANT CAPITAL
Cormorant Capital facilitates the growth of real estate-operator and owner clients by co-investing in select transactions. Cormorant Capital was established to respond to such equity needs, while maintaining alignment of interests between partners. Such alignment is accomplished not only through balanced joint-venture economics, but also by identifying owner/operator value-add in specific products and geographies sought after by investors.
CORMORANT CAPITAL
Industry:
Finance Financial Services
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Font Awesome Apache
Similar Organizations
Techstars Ventures
Techstars Ventures is a venture capital firm that empowers entrepreneurs to bring new technologies to the market.
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-12-07 | Freenome | Cormorant Capital investment in Series D - Freenome | 300 M USD |
| 2021-02-07 | Shoreline Biosciences | Cormorant Capital investment in Series A - Shoreline Biosciences | 43 M USD |
| 2020-11-09 | Prometheus Biosciences | Cormorant Capital investment in Private Equity Round - Prometheus Biosciences | 130 M USD |
| 2020-10-19 | VectivBio | Cormorant Capital investment in Venture Round - VectivBio | 110 M USD |
| 2019-07-09 | Revolution Medicines | Cormorant Capital investment in Series C - Revolution Medicines | 100 M USD |
| 2019-04-24 | Satsuma Pharmaceuticals | Cormorant Capital investment in Series B - Satsuma Pharmaceuticals | 62 M USD |
| 2019-01-23 | BridgeBio Pharma | Cormorant Capital investment in Series D - BridgeBio Pharma | 299.2 M USD |
| 2019-01-03 | Cabaletta Bio | Cormorant Capital investment in Series B - Cabaletta Bio | 50 M USD |
| 2018-04-02 | CMAB BioPharm | Cormorant Capital investment in Series B - CMAB BioPharm | 34 M USD |
| 2017-09-13 | BridgeBio Pharma | Cormorant Capital investment in Series C - BridgeBio Pharma | 135 M USD |